TNFSF11 and hypercalcemia disease: For example, the anti-resorptive agent denosumab (a monoclonal antibody against RANKL) has been approved by the U.S. Food and Drug Administration for the treatment of osteoporosis, hypercalcemia, and bone destruction in myeloma patients20.